Merck & Co. (MRK) Shares Sold by Gould Asset Management LLC CA

Gould Asset Management LLC CA decreased its position in Merck & Co. (NYSE:MRK) by 5.4% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 21,636 shares of the company’s stock after selling 1,241 shares during the period. Merck & Co. makes up 0.5% of Gould Asset Management LLC CA’s portfolio, making the stock its 27th largest position. Gould Asset Management LLC CA’s holdings in Merck & Co. were worth $1,217,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in the company. Krilogy Financial LLC lifted its position in Merck & Co. by 0.4% in the 2nd quarter. Krilogy Financial LLC now owns 3,129 shares of the company’s stock valued at $201,000 after acquiring an additional 11 shares in the last quarter. Balentine LLC lifted its position in Merck & Co. by 1.0% in the 2nd quarter. Balentine LLC now owns 2,107 shares of the company’s stock valued at $135,000 after acquiring an additional 20 shares in the last quarter. Thompson Davis & CO. Inc. lifted its position in Merck & Co. by 0.9% in the 2nd quarter. Thompson Davis & CO. Inc. now owns 4,313 shares of the company’s stock valued at $276,000 after acquiring an additional 40 shares in the last quarter. Southeast Asset Advisors Inc. lifted its position in Merck & Co. by 2.0% in the 2nd quarter. Southeast Asset Advisors Inc. now owns 5,428 shares of the company’s stock valued at $348,000 after acquiring an additional 105 shares in the last quarter. Finally, Coastline Trust Co lifted its position in Merck & Co. by 0.3% in the 2nd quarter. Coastline Trust Co now owns 57,399 shares of the company’s stock valued at $3,679,000 after acquiring an additional 150 shares in the last quarter. 74.60% of the stock is owned by institutional investors.

How to Become a New Pot Stock Millionaire

Shares of MRK stock opened at $58.92 on Thursday. The company has a current ratio of 1.33, a quick ratio of 1.06 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $158,131.55, a PE ratio of 14.80, a PEG ratio of 2.45 and a beta of 0.78. Merck & Co. has a 52-week low of $52.83 and a 52-week high of $66.41.

Merck & Co. (NYSE:MRK) last issued its earnings results on Friday, February 2nd. The company reported $0.98 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.94 by $0.04. The company had revenue of $10.43 billion for the quarter, compared to analysts’ expectations of $10.48 billion. Merck & Co. had a net margin of 6.40% and a return on equity of 28.61%. Merck & Co.’s quarterly revenue was up 3.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.89 EPS. equities analysts forecast that Merck & Co. will post 4.16 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Friday, April 6th. Stockholders of record on Thursday, March 15th were issued a $0.48 dividend. The ex-dividend date was Wednesday, March 14th. This represents a $1.92 dividend on an annualized basis and a dividend yield of 3.26%. Merck & Co.’s payout ratio is 48.24%.

Several equities research analysts recently commented on the stock. Jefferies Group set a $55.00 price objective on shares of Merck & Co. and gave the company a “hold” rating in a research report on Friday, March 23rd. ValuEngine cut shares of Merck & Co. from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. DZ Bank raised shares of Merck & Co. from a “hold” rating to a “buy” rating in a research report on Tuesday, February 13th. Morgan Stanley boosted their price objective on shares of Merck & Co. from $60.00 to $63.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 7th. Finally, Credit Suisse Group cut their price objective on shares of Merck & Co. from $67.00 to $66.00 and set an “outperform” rating on the stock in a research report on Monday, February 5th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $66.83.

In other news, Director Wendell P. Weeks sold 5,000 shares of the company’s stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $53.57, for a total value of $267,850.00. Following the sale, the director now directly owns 5,100 shares of the company’s stock, valued at approximately $273,207. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Weir Mirian M. Graddick sold 24,000 shares of the company’s stock in a transaction dated Monday, April 16th. The shares were sold at an average price of $58.00, for a total transaction of $1,392,000.00. The disclosure for this sale can be found here. 0.32% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: “Merck & Co. (MRK) Shares Sold by Gould Asset Management LLC CA” was originally posted by Week Herald and is the sole property of of Week Herald. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://weekherald.com/2018/04/19/merck-co-mrk-shares-sold-by-gould-asset-management-llc-ca.html.

About Merck & Co.

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Institutional Ownership by Quarter for Merck & Co. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply